Boichuk S.; Galembikova A.; Dunaev P.; Valeeva E.; Shagimardanova E.; Gusev O.; Khaiboullina S.
(2017)
© 2017 by the authors. The fact that most gastrointestinal stromal tumors (GISTs) acquire resistance to imatinib (IM)-based targeted therapy remains the main driving force to identify novel molecular targets that are capable ...